Dianthus Therapeutics (NASDAQ:DNTH) and UCB (OTCMKTS:UCBJF) Head to Head Analysis

UCB (OTCMKTS:UCBJF) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

Institutional & Insider Ownership

47.5% of Dianthus Therapeutics shares are held by institutional investors. 16.6% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares UCB and Dianthus Therapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UCB	$5.27 billion	N/A	$371.20 million	N/A	N/A
Dianthus Therapeutics	$2.83 million	267.57	-$43.56 million	N/A	N/A

UCB has higher revenue and earnings than Dianthus Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and price targets for UCB and Dianthus Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UCB	0	0	3	0	3.00
Dianthus Therapeutics	0	0	5	0	3.00

Dianthus Therapeutics has a consensus target price of $42.40, indicating a potential upside of 64.34%. Given Dianthus Therapeutics’ higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than UCB.

Profitability

This table compares UCB and Dianthus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
UCB	N/A	N/A	N/A
Dianthus Therapeutics	N/A	-45.49%	-42.54%

Risk and Volatility

UCB has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Summary

Dianthus Therapeutics beats UCB on 5 of the 9 factors compared between the two stocks.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.